There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes and obesity, according to the EU medicines regulator. Along with ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can cause cancer ...

Wall Street bankers shift focus to busy 2026 after cashing in on big deals Wall Street's investment bankers expect to stay busy this year after reaping a windfall from big-ticket deals and stock ...

November 24, 2025 • Our annual reading guide returns with 380+ new titles handpicked by NPR staff and trusted critics. Find 13 years of recommendations all in one place — that's more than 4,000 great ...